Tumor suppressive function of IGF2BP1 in gastric cancer through decreasing MYC
Cancer Science · 2024
DOI: 10.1111/cas.16047 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Ning Ding und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Stomach Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: China Postdoctoral Science Foundation, Natural Science Foundation of Zhejiang Province.
Abstract (Originalsprache)
Gastric cancer is one of the most common causes of cancer‐related death worldwide. The N 6 ‐methyladenosine (m 6 A) reader IGF2BP1 (insulin‐like growth factor‐2 mRNA binding protein 1) has been reported to promote cancer progression by stabilizing oncogenic mRNAs through its m 6 A‐binding activity in some tumors. However, the role of IGF2BP1 in gastric carcinogenesis remains unclear. In this study, we found that IGF2BP1 is significantly downregulated in tumor tissues from patients with gastric cancer. Lower expression of IGF2BP1 is associated with poor prognosis. Gastric cancer cell proliferation is suppressed by IGF2BP1 in an m 6 A‐dependent manner. Additionally, IGF2BP1 is able to significantly attenuate tumor growth of gastric cancer cells. Further m 6 A sequencing and m 6 A‐RNA immunoprecipitation assays show that MYC (c‐myc proto‐oncogene) mRNA is a target transcript of IGF2BP1 in gastric cancer cells. IGF2BP1 inhibits gastric cancer cell proliferation by reducing the mRNA and protein expression of MYC . Mechanistically, IGF2BP1 promotes the degradation of MYC mRNA and inhibits its translation efficiency. Taken together, these data suggest that IGF2BP1 plays a tumor‐suppressive role in gastric carcinogenesis by downregulating MYC in an m 6 A‐dependent manner, thereby making the IGF2BP1‐ MYC axis a potential target for gastric cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
- Zhejiang University Cancer Center, Hangzhou, China.
- Institution of Gastroenterology, Zhejiang University, Hangzhou, China.
- Department of General Surgery, First Affiliated Hospital of Anhui Medical University, Hefei, China.
- Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Hangzhou, China.
- Department of Hepatobiliary and Pancreatic Surgery, Hangzhou First People's Hospital, Hangzhou, China.
ORCID-Profile: Ning Ding
Förderung
- China Postdoctoral Science Foundation
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Ding, N., Cao, G., Wang, Z., Xu, S., & Chen, W. (2024). Tumor suppressive function of IGF2BP1 in gastric cancer through decreasing MYC. Cancer Science. https://doi.org/10.1111/cas.16047
Vancouver
Ding N, Cao G, Wang Z, Xu S, Chen W. Tumor suppressive function of IGF2BP1 in gastric cancer through decreasing MYC. Cancer Science. 2024. doi:10.1111/cas.16047
BibTeX
@article{Ding2024,
author = {Ding, Ning and Cao, Guodong and Wang, Zhuo and Xu, Shengjun and Chen, Wenwen},
title = {Tumor suppressive function of IGF2BP1 in gastric cancer through decreasing MYC},
journal = {Cancer Science},
year = {2024},
doi = {10.1111/cas.16047}
}
EUVIMED